Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2009

View Archived Issues

Dapagliflozin improves glycemic control in type 2 diabetes patients and in preclinical models

Celator completes enrollment in phase II clinical trial of CPX-351 in untreated AML

Signs of activity seen with PTC-299 in metastatic breast cancer patients

Trigone-specific injection of botulinum toxin type B improves idiopathic detrusor overactivity

Long-term improvements in signs of vaginal atrophy seen with ospemifene

Clinical data support safety and efficacy of S-equol in postmenopausal women

Nicorandil improves clinical outcomes in acute ST segment elevation myocardial infarction

Vaccine to treat cocaine dependence evaluated in phase IIb study / News in Context

Aquinox selects AQX-1125 as lead clinical candidate in SHIP program

Vanda and Novartis sign agreement for antipsychotic Fanapt in the U.S. and Canada

BioMimetic Therapeutics presents topline data from its Augment Bone Graft trial

Phytopharm reports results for Cogane in Parkinson's disease

EMEA grants orphan drug designation to ARQ-197 for soft tissue sarcoma

Myriad identifies IND candidate targeting IKK epsilon

Pieris reports preclinical development of VEGF antagonist PRS-050

OPKO Health acquires lead NK1 compounds from Schering-Plough

Newron returns rights to HF-0420 and pursues development of HF-0220

Depomed reports results of phase III trials of Serada for menopausal hot flashes

Raptor reports interim results from phase IIa clinical trial of DR cysteamine in NASH

Inovio Biomedical reports results on SynCon A/H1N1 influenza vaccine

CSL donates 3 million doses of pandemic influenza A (H1N1) vaccine to WHO

European Commission grants marketing authorization to Boehringer's Sifrol for PD

BMS describes NS5A protein inhibitors for the treatment of HCV infection

Servier claims dual nitric oxide donors and diuretic agents for treating hypertension

German scientists report EGFR and HER2 tyrosine kinase inhibitors for cancer treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...